Meeting
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
Authors
Martin Reck
Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany
Martin Reck , Hyatt P. DeGreen II, Andrea L. Rose , Nick Pavlakis , Sofie Maria Derjcke , Jasna Radic , Nina Jeppesen , Michael Thomas , Gyorgy Losonczy , Ewa Kalinka-Warzocha , Lydia Mary Dreosti , Mustafa Ozguroglu , Pieter E. Postmus , Christoph Helwig , Vikram Chand , Jean-Marie Cuillerot , Virginie Westeel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02576574
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS9105)
DOI
10.1200/JCO.2016.34.15_suppl.TPS9105
Abstract #
TPS9105
Poster Bd #
425a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
First Author: David Paul Carbone
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2016 ASCO Annual Meeting
Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non–small cell lung carcinoma (NSCLC): KEYNOTE-189.
First Author: Richard Delmar Hall
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu